Scorpius Holdings Inc. · OTC:SCPX
Scorpius — IPO Roadshow (May 2024)
17 slides from Scorpius's IPO roadshow presentation, May 3, 2024
Slide 1: Scorpius Biomanufacturing Investor Presentation – May 2024
Scorpius Biomanufacturing A rapidly growing, highly scalable biologics Contract Development & Manufacturing Organization (CDMO) Investor Presentation – May 2024 NYSE American: SCPX Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333 - 279092 May 3, 2024
Slide 2: Forward-looking statements
This presentation includes statements that are, or may be deemed, “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended . In some cases, these forward - looking statements can be identified by the use of forward - looking terminology,
Slide 3: Free Writing Prospectus
Free Writing Prospectus This presentation highlights basic information about us and the proposed offering. Because it is a summary, it does not conta in all of the information that you should consider before investing. We have filed a registration statement (including a prospectus supplement and the
Slide 4: Full-Service CDMO Focused on Biologic Production for the Middle Market
Full - Service CDMO Focused on Biologic Production for the Middle Market Scorpius seeks to differentiate itself from competitors with a comprehensive mix of service offerings and a nimble, “boutique” approach to project planning and execution 4
Slide 5: Investment Highlights
Investment Highlights » Pure - play biologics CDMO offering a comprehensive range of services from process and analytical development through clinical - stage and small - scale commercial cGMP manufacturing » Growing demand for Contract Development & Manufacturing Organization (CDMO) services and si
Slide 6: Leadership Team
Leadership Team Joe Payne President and Chief Operating Officer 20+ Years Of Experience Alcami, Tergus, Teva Brian O’Mara VP, Process Sciences 20+ Years Of Experience Ambrx, Bristol - Myers Squibb, Genencor, Wyeth Stephan Kutzer Senior Advisor 25+ Years Of Experience Alcami, Lonza Matt LeClair VP, M
Slide 7: Growing Market Due to Rising Demand and Expanding Treatment Scope
Scorpius is positioned to take advantage of rapid growth of the biopharmaceutical market now with a rising demand for biologics and the aging global population *Precedence Research, Global Biologics Market, July 2023 Growing Market Due to Rising Demand and Expanding Treatment Scope 7 What Are Biopha
Slide 8: Increased Biologic Demand: Large Molecule CDMO Market
Large Molecule Drug Substance CDMO Market size is poised to grow from $10.86B in 2022 to $21B by 2030, growing at a CAGR of 8.6% in the forecast period (2023 - 2030)* *SkyQuest Large Molecule Industry Forecast, July 2023 Over the last decade, R&D spending has steadily shifted from its focus on small
Slide 9: Business History
Nov ’20: Scorpius BioManufacturing is founded Aug ’21: Broke ground on San Antonio, TX facility Q4 ’22: Onboarded first client for microbial commercial contract Oct ’22: Opened San Antonio facility 2H ‘21 1H ‘22 2H ‘22 1H ‘23 2H ‘23 2H ‘20 1H ‘21 In the two years since breaking ground, Scorpius is c
Slide 10: Manufacturing Snapshot
Clinical - scale biomanufacturing in San Antonio, TX located in the heart of a thriving innovation district Highly skilled scientific and manufacturing leadership team U.S. - sourced supply chain with US and international customers In - house process development and analytical services including mic
Slide 11: Supported Drug Modalities
11 Supported Drug Modalities Mammalian Cell Culture » Antibody Production » Monoclonals, Bi - Specifics » Recombinant Therapeutic Proteins » Allogeneic and Autologous Cell Therapy » Fc Fusions » Cells, Exosomes, Secretome Microbial Fermentation » Recombinant Therapeutic Proteins & Enzyme Products »
Slide 12: BioMap and BIOSECURE ACT Foster US Production of Advanced Biologics
BioMap and BIOSECURE ACT Foster US Production of Advanced Biologics 12 The BIOSECURE Act (“the Act”), would prohibit executive agencies from contracting with any company with commercial arrangements with a “biotechnology company of concern” which generally means a company that is headquartered in or
Slide 13: Summary Statement of Operations
Summary Statement of Operations 13 » Approx. $65M in total expenditures developing Scorpius’ CDMO business since inception, including approx. $32M of direct facility investment (PP&E, etc.). » Revenue of $4.8M in Q4, an increase of 570% compared to Q3, demonstrating execution of customer contract wo
Slide 14: Balance Sheet and Capitalization Table
As of December 31, 2023 Balance Sheet $2,391,480 Cash and short - term investments $4,760,859 Total Current Assets $51,037,627 Total Assets 1 $10,100,138 Total Current Liabilities 2 $22,743,292 Total Liabilities 3 $28,294,335 Stockholders’ Equity » Capital equipment investment into facility 100% com
Slide 15: 2024 Goals & Milestones
2024 Goals & Milestones » Execute Contracts: Streamline operations to scale and execute on $18M existing pipeline of signed manufacturing contracts. » Increase Capacity: Optimize facilities to increase current $50M+ capacity. » Diversify Revenue: Expand revenue streams with the initiation of mammali
Slide 16: Summary
Summary 16 » Growing demand for Contract Development & Manufacturing Organization (CDMO) services and significant shortage of dedicated clinical - scale manufacturing capacity within the industry » Scorpius began 2023 with $3M of signed manufacturing contracts, which has grown to over $18M in signed
Slide 17: Media and Investor Relations Contact
Media and Investor Relations Contact David Waldman ir@scorpiusbiologics.com 17